Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
40S ribosomal protein S14 is a cytoplasmic structural component of the eukaryotic small ribosomal subunit (40S), belonging to the S11P family of ribosomal proteins. It is essential for protein synthesis and ribosome stability. While not a receptor, enzyme, or transporter, RPS14 participates in fundamental biological processes, and its mutation or deficiency is associated with bone marrow failure syndromes and cancer risk. Certain drugs like emetine interact with the ribosome, and resistance may arise from mutations in RPS14. Loss of RPS14 is specifically implicated in the clinical features of 5q- syndrome, including anemia and risk of acute myeloid leukemia. Because ribosomal proteins are vital for survival, they are generally not considered therapeutic drug targets but may serve as biomarkers in hematological disorders.
Protein synthesis inhibition (by emetine, in resistant cells) Not a direct therapeutic target for drugs in current clinical use
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on 40S ribosomal protein S14 (RPS14).